Phenotypes of Non-Alcoholic Fatty Liver Disease in Different Regions of the Russian Federation, Diagnostic and Therapeutic Approach in Clinical Practice

Aim: to present data on the prevalence of various phenotypes of non-alcoholic fatty liver disease (NAFLD), the features of its diagnosis and treatment in various regions of the Russian Federation following a meeting of chief gastroenterologists.

Key points. Non-alcoholic fatty liver disease (NAFLD) holds the leading position among non-infectious liver diseases in the Russian Federation, its prevalence is 37.3 % and does not tend to decrease.

To get information on various aspects of NAFLD diagnosis and treatment, opinion of 18 chief external regional gastroenterologists and leading specialists in the field of liver diseases was studied by analyzing the responses to questions specially formulated for them. Information on the situation in the Ural, Privolzhsky, Southern, Central and North-western Federal Districts was obtained. Regional statistics on the prevalence of NAFLD and its certain phenotypes (steatosis, steatohepatitis, cirrhosis), diagnostic instruments and treatment approaches which are used in clinical practice, as well as on the most common associated conditions was presented.

Conclusions. The collected information allows to improve both administrative and treatment and diagnostic-related activities in managing patients suffering from this disease.

1. Jichitu A., Bungau S., Stanescu A.M.A., Vesa C.M., Toma M.M., Busteaet C., et al. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics (Basel). 2021;11(4):689. DOI: 10.3390/diagnostics110406893

2. Ivashkin V.T., Drapkina O.M., Mayev I.V., Trukhmanov A.S., Blinov D.V., Palgova L.K., et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. Rus J Gastroenterol Hepatol Coloproctol. 2015;25(6):31—41 (In Russ.).

3. Shakhrun O.O. Emergence of Cardiometabolic Disorders in Patients with Insulin Resistance-Associated NAFLD. Synopsis of doctoral thesis, М., 2019.

4. Komova A.G., Mayevskaya M.V., Ivashkin V.T. Principles of effective out-patient diagnostics of diffuse liver diseases. Rus J Gastroenterol Hepatol Coloproctol. 2014;24(5):36-41 (In Russ.).

5. Bogomolov P.O., M.V. Matsievich, A.O. Bueverov, Kokina K.Yu., Voronkova N.V., Beznosenko V.D. Liver cirrhosis in the Moscow Region: figures and facts. Almanac of clinical medicine. 2018;46(1):59—67. DOI: 10.18786/2072-0505-2018-46-1-59-67

6. Maevskaya M.V., Novruzbekov M.S., Borovkov I.M., Trofimova D.G., Jarkova M.S., Lunkov V.D., Lutsik K.N., Olisov O.D. Structure of Patients with Hepatocellular Cancer (data analysis from two specialized centers). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(2):58-67. DOI: 10.22416/1382-4376-2020-30-2-58-67

7. I.V. Mayev et. al. Hepatoprotective Potential of ademetionine: Physiological Role and Possibilities of Clinical Use. Meditsinskiy vestnik MVD (Medical Bulletin of the Ministry of Internal Affairs) 2013; 67-72.

8. Mato J.M., Mart nez-Chantar M.L., Lu S.C. S-adenosylmethionine metabolism and liver disease. Ann Hepatol. 2013;12(2):183-189.

9. Alonso, C., Fernandez-Ramos D., Varela-Rey M., Martinez-Arranz I., Navasa N., Liempd S.M.V., et al. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. Gastroenterology. 2017;152(6):1449e7-1461e7. DOI: 10.1053/j.gastro.2017.01.015

10. Baranovsky A.Yu., Raikhelson K.L., Marchenko N.V. Use of Heptral in Non-Alcoholic Steatohepatitis Treatment. Zdorov'e Ukrainy (Public Health in Ukraine). 2010; 42-43.

11. Baiming L. Observation of the efficacy of S-adenosylmethionine in the treatment of non-alcoholic fatty liver disease. Chinese Hepatol. 2011;16:350-351.

12. Diaz Belmont A., Dominguez Henkel R., Uribe Ancira F. SAMe parenteral en el tratamiento de la hepatopatia alcoholica comparativo contra placebo [Parenteral S-adenosylmethionine compared to placebos in the treatment of alcoholic liver diseases]. An Med Interna. 1996;13(1):9-15. (In Spanish).

13. Vendemiale G., Altomare E., Trizio T., Grazie C.L., Padova C.D., Salerno M.T., et al. Effects of Oral S-Adenosyl-l-Methionine on Hepatic Glutathione in Patients with Liver Disease. 1989;24(4):407-415. DOI: 10.3109/00365528909093067

14. Younossi Z.M., Paik J.M., Golabi P., Younossi Y., Henry L., Nader F. The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease: Data from National Health and nutrition examination survey 2005-2010 and 2017-2018. Liver Int. 2022;42(12):2646-2661. DOI: 10.1111/liv.15437

15. Raikhelson K.L., Kondrashina E.A. Adamethionine in the treatment of fatigue in liver diseases: A systematic review. Ter Arkh. 2019;91(2):134-142. DOI: 10.26442/00403660.2019.02.00013